Connect Biopharma Holdings Limited Board of Directors

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Ms. Lisa Peraza CPA

Ms. Lisa Peraza CPA

Vice President of Finance

Mr. Jeff Cohn J.D.

Mr. Jeff Cohn J.D.

General Counsel & Corporate Secretary

Dr. Raul Collazo Ph.D.

Dr. Raul Collazo Ph.D.

VP & Global Head of Medical Affairs

Ms. Kimberly J. Manhard

Ms. Kimberly J. Manhard

Chief Development Officer

Dr. Srikanth Pendyala M.D.

Dr. Srikanth Pendyala M.D.

Senior Vice President of Clinical Development(Consultant)

Dr. Lei Sun Ph.D.

Dr. Lei Sun Ph.D.

VP of Biologics & Head of CMC

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.